20/20 Biolabs, Inc. 1Q 2026: Revenue $353.38K, EPS ($0.28) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
20/20 Biolabs, Inc. reported a revenue decline to $353.38K in Q1 2026, with a net loss of $2.12M and diluted EPS of ($0.28), compared to ($0.16) a year ago. The drop in revenue was attributed to lower OneTest and BioCheck sales, and a major OneTest renewal was delayed. The company launched OneTest for Longevity and increased R&D spending to support its product pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments